Literature DB >> 18084639

Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity.

Balapal S Basavarajappa1.   

Abstract

The endocannabinoid signaling system is composed of the cannabinoid receptors; their endogenous ligands, the endocannabinoids; the enzymes that produce and inactivate the endocannabinoids; and the endocannabinoid transporters. The endocannabinoids are a new family of lipidic signal mediators, which includes amides, esters, and ethers of long-chain polyunsaturated fatty acids. Endocannabinoids signal through the same cell surface receptors that are targeted by Delta(9)-tetrahydrocannabinol (Delta(9)THC), the active principles of cannabis sativa preparations like hashish and marijuana. The biosynthetic pathways for the synthesis and release of endocannabinoids are still rather uncertain. Unlike neurotransmitter molecules that are typically held in vesicles before synaptic release, endocannabinoids are synthesized on demand within the plasma membrane. Once released, they travel in a retrograde direction and transiently suppress presynaptic neurotransmitter release through activation of cannabinoid receptors. The endocannabinoid signaling system is being found to be involved in an increasing number of pathological conditions. In the brain, endocannabinoid signaling is mostly inhibitory and suggests a role for cannabinoids as therapeutic agents in central nervous system (CNS) disease. Their ability to modulate synaptic efficacy has a wide range of functional consequences and provides unique therapeutic possibilities. The present review is focused on new information regarding the endocannabinoid signaling system in the brain. First, the structure, anatomical distribution, and signal transduction mechanisms of cannabinoid receptors are described. Second, the synthetic pathways of endocannabinoids are discussed, along with the putative mechanisms of their release, uptake, and degradation. Finally, the role of the endocannabinoid signaling system in the CNS and its potential as a therapeutic target in various CNS disease conditions, including alcoholism, are discussed.

Entities:  

Keywords:  Alcoholism; CB1 receptors; CNS; alcohol-drinking behavior; endocannabinoids; reward; synaptic plasticity; therapy

Year:  2007        PMID: 18084639      PMCID: PMC2139910          DOI: 10.2174/157015907780866910

Source DB:  PubMed          Journal:  Curr Neuropharmacol        ISSN: 1570-159X            Impact factor:   7.363


  311 in total

1.  Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations.

Authors:  N Hájos; I Katona; S S Naiem; K MacKie; C Ledent; I Mody; T F Freund
Journal:  Eur J Neurosci       Date:  2000-09       Impact factor: 3.386

2.  Coupling of the expressed cannabinoid CB1 and CB2 receptors to phospholipase C and G protein-coupled inwardly rectifying K+ channels.

Authors:  B Y Ho; Y Uezono; S Takada; I Takase; F Izumi
Journal:  Receptors Channels       Date:  1999

Review 3.  Endocannabinoids in pain modulation.

Authors:  J M Walker; S M Huang
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2002 Feb-Mar       Impact factor: 4.006

4.  Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism.

Authors:  M P Caulfield; D A Brown
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

5.  Molecular composition of the endocannabinoid system at glutamatergic synapses.

Authors:  István Katona; Gabriella M Urbán; Matthew Wallace; Catherine Ledent; Kwang-Mook Jung; Daniele Piomelli; Ken Mackie; Tamás F Freund
Journal:  J Neurosci       Date:  2006-05-24       Impact factor: 6.167

6.  Effects of SR141716A on ethanol and sucrose self-administration.

Authors:  C S Freedland; A L Sharpe; H H Samson; L J Porrino
Journal:  Alcohol Clin Exp Res       Date:  2001-02       Impact factor: 3.455

7.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors:  Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

8.  Postsynaptic spike firing reduces synaptic GABAA responses in hippocampal pyramidal cells.

Authors:  T A Pitler; B E Alger
Journal:  J Neurosci       Date:  1992-10       Impact factor: 6.167

9.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

10.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

Authors:  C C Felder; K E Joyce; E M Briley; J Mansouri; K Mackie; O Blond; Y Lai; A L Ma; R L Mitchell
Journal:  Mol Pharmacol       Date:  1995-09       Impact factor: 4.436

View more
  33 in total

1.  Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD).

Authors:  Matthew W Elmes; Martin Kaczocha; William T Berger; KwanNok Leung; Brian P Ralph; Liqun Wang; Joseph M Sweeney; Jeremy T Miyauchi; Stella E Tsirka; Iwao Ojima; Dale G Deutsch
Journal:  J Biol Chem       Date:  2015-02-09       Impact factor: 5.157

Review 2.  Adaptations of striatal endocannabinoid system during stress.

Authors:  Silvia Rossi; Valentina De Chiara; Alessandra Musella; Giorgia Mataluni; Lucia Sacchetti; Giorgio Bernardi; Alessandro Usiello; Diego Centonze
Journal:  Mol Neurobiol       Date:  2009-03-07       Impact factor: 5.590

Review 3.  Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal.

Authors:  J L Scavone; R C Sterling; E J Van Bockstaele
Journal:  Neuroscience       Date:  2013-04-24       Impact factor: 3.590

Review 4.  Endocannabinoids and traumatic brain injury.

Authors:  Esther Shohami; Ayelet Cohen-Yeshurun; Lital Magid; Merav Algali; Raphael Mechoulam
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

5.  Design and evaluation of a novel fluorescent CB2 ligand as probe for receptor visualization in immune cells.

Authors:  Ravil R Petrov; Maria E Ferrini; Zeina Jaffar; Charles M Thompson; Kevan Roberts; Philippe Diaz
Journal:  Bioorg Med Chem Lett       Date:  2011-08-03       Impact factor: 2.823

6.  Emerging Roles of Cannabinoids and Synthetic Cannabinoids in Clinical Experimental Models.

Authors:  Paula Morales; Patricia H Reggio
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Comorbid mood, psychosis, and marijuana abuse disorders: a theoretical review.

Authors:  Natascha Wilson; Jean Lud Cadet
Journal:  J Addict Dis       Date:  2009-10

8.  Pharmacological enhancement of endocannabinoid signaling reduces the cholinergic toxicity of diisopropylfluorophosphate.

Authors:  Anuradha Nallapaneni; Jing Liu; Subramanya Karanth; Carey Pope
Journal:  Neurotoxicology       Date:  2008-08-13       Impact factor: 4.294

Review 9.  Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia.

Authors:  Marc Fakhoury
Journal:  Mol Neurobiol       Date:  2016-01-15       Impact factor: 5.590

10.  Anandamide-CB1 receptor signaling contributes to postnatal ethanol-induced neonatal neurodegeneration, adult synaptic, and memory deficits.

Authors:  Shivakumar Subbanna; Madhu Shivakumar; Delphine Psychoyos; Shan Xie; Balapal S Basavarajappa
Journal:  J Neurosci       Date:  2013-04-10       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.